Payment overview · 2025
General Payments
$396.75
11 reported records · 5 companies
Healthcare provider profile · identity verified
Willard Gene Burks, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WYNNE, AR · NPI 1619082310
Verified facts
What the public records show
CMS Open Payments records show Willard Gene Burks, M.D. received $396.75 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.42 | 51.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $115.38 | 29.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.79 | 7.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.42 | 7.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.74 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.75 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $79.42 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.67 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 267 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
267 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 622 | 124 |
| Pantoprazole Sodium | Pantoprazole Sodium | 622 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 619 | 144 |
| Lorazepam | Lorazepam | 589 | 103 |
| Furosemide | Furosemide | 577 | 150 |
| Potassium Chloride | Potassium Chloride | 548 | 119 |
| Gabapentin | Gabapentin | 449 | 88 |
| Tramadol Hcl | Tramadol Hcl | 430 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 364 | 68 |
| Metformin Hcl | Metformin Hcl | 356 | 78 |
| Simvastatin | Simvastatin | 355 | 73 |
| Cephalexin | Cephalexin | 339 | 207 |
| Omeprazole | Omeprazole | 324 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 314 | 65 |
| Glimepiride | Glimepiride | 275 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 274 | 70 |
| Eliquis | Apixaban | 267 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 264 | 50 |
| Losartan Potassium | Losartan Potassium | 262 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 253 | 46 |
| Carvedilol | Carvedilol | 237 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 44 |
| Lisinopril | Lisinopril | 221 | 44 |
| Allopurinol | Allopurinol | 219 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 42 |
| Sertraline Hcl | Sertraline Hcl | 183 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 182 | 42 |
| Meloxicam | Meloxicam | 179 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 38 |
| Famotidine | Famotidine | 175 | 42 |
| Trazodone Hcl | Trazodone Hcl | 161 | 24 |
| Warfarin Sodium | Warfarin Sodium | 154 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 148 | 52 |
| Dicyclomine Hcl | Dicyclomine Hcl | 142 | 46 |
| Alprazolam | Alprazolam | 141 | 20 |
| Atenolol | Atenolol | 137 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 29 |
| Clonidine Hcl | Clonidine Hcl | 129 | 26 |
| Prednisone | Prednisone | 125 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 30 |
| Baclofen | Baclofen | 120 | 58 |
| Donepezil Hcl | Donepezil Hcl | 120 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 119 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 117 | 21 |
| Pregabalin | Pregabalin | 114 | 17 |
| Diazepam | Diazepam | 113 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 108 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 106 | 27 |
| Montelukast Sodium | Montelukast Sodium | 104 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 103 | 23 |
| Sucralfate | Sucralfate | 98 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 17 |
| Xarelto | Rivaroxaban | 88 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 18 |
| Levetiracetam | Levetiracetam | 82 | 11 |
| Meclizine Hcl | Meclizine Hcl | 82 | 25 |
| Jardiance | Empagliflozin | 81 | 15 |
| Clonazepam | Clonazepam | 79 | 12 |
| Nitroglycerin | Nitroglycerin | 79 | 32 |
| Methocarbamol | Methocarbamol | 77 | 27 |
| Celecoxib | Celecoxib | 76 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 72 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 45 |
| Spironolactone | Spironolactone | 71 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 15 |
| Azithromycin | Azithromycin | 65 | 55 |
| Naproxen | Naproxen | 65 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 49 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 12 |
| Ozempic | Semaglutide | 63 | suppressed |
| Chlorthalidone | Chlorthalidone | 61 | 12 |
| Memantine Hcl | Memantine Hcl | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 59 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 56 | 17 |
| Ezetimibe | Ezetimibe | 55 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | 14 |
| Metformin Hcl Er | Metformin Hcl | 54 | 13 |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Levofloxacin | Levofloxacin | 52 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 11 |
| Enalapril Maleate | Enalapril Maleate | 51 | suppressed |
| Sotalol | Sotalol Hcl | 51 | 13 |
| Lovastatin | Lovastatin | 50 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Glipizide | Glipizide | 48 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 33 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | suppressed |
| Lamotrigine | Lamotrigine | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Fluconazole | Fluconazole | 42 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 20 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Digoxin | Digoxin | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 25 |
| Temazepam | Temazepam | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Mupirocin | Mupirocin | 32 | 18 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 12 |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Haloperidol | Haloperidol | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Cilostazol | Cilostazol | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Methadone Hcl | Methadone Hcl | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Valsartan | Valsartan | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Metolazone | Metolazone | 18 | 11 |
| Risperidone | Risperidone | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 17 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Daptomycin | Daptomycin | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Meropenem | Meropenem | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Emtricitabine | Emtricitabine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.75 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, FARXIGA, NURTEC ODT, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error